Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:

NCT ID: NCT04460105 Withdrawn - COVID-19 Pneumonia Clinical Trials

Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia

Start date: October 31, 2020
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetic and pharmacodynamics of lanadelumab administered by intravenous (IV) infusion when added to standard-of-care (SoC) in adults hospitalized with COVID-19 pneumonia.

NCT ID: NCT04459702 Withdrawn - COVID-19 Clinical Trials

A Study of Combination Therapies to Treat COVID-19 Infection

Start date: July 2020
Phase: Phase 2
Study type: Interventional

This study seeks to determine whether dual or quadruple therapy is more effective in treating COVID-19.

NCT ID: NCT04456426 Withdrawn - COVID Clinical Trials

Characteristics of Patients With COVID-19 in Meta State, Colombia

Start date: September 1, 2021
Phase:
Study type: Observational

This observational study aims to collect detailed clinical information on confirmed or suspected patients of COVID-19 treated in hospitals from Meta State, Colombia. The objectives are: 1. To establish the characteristics of patients and healthcare workers treated with COVID-19. 2. To assess previous predisposing morbidity. 3. To detail clinical factors associated with complications. 4. To profile clinical indicators for severity and outcomes.

NCT ID: NCT04456088 Withdrawn - COVID-19 Clinical Trials

Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (CANADA Trial)

Start date: July 15, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this open label, 2-phase, study is to obtain information on the safety of 80 ppm and the safety and efficacy of 150 ppm Nitric Oxide given in addition to the standard of care of patients with COVID-19 caused by SARS-CoV-2.

NCT ID: NCT04455958 Withdrawn - Clinical trials for Malignant Solid Neoplasm

Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last Year

Start date: May 1, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well lopinavir/ritonavir works in treating COVID-19 positive patients with cancer and a weakened immune system (immune-suppression) in the last year and have mild or moderate symptoms caused by COVID-19. Lopinavir/ritonavir may help to lessen or prevent COVID-19 symptoms from getting worse in cancer patients.

NCT ID: NCT04454398 Withdrawn - Covid-19 Clinical Trials

Study to Evaluate STI-1499 (COVI-GUARD) in Patients With Moderate COVID-19

Start date: September 2020
Phase: Phase 1
Study type: Interventional

Randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of STI-1499 (COVI-GUARDâ„¢) in hospitalized patients with moderate COVID-19

NCT ID: NCT04453891 Withdrawn - COVID-19 Clinical Trials

Hexoskin Feasibility Study With COVID-19 Patients

Start date: July 15, 2022
Phase:
Study type: Observational

This pilot study aims to investigate the feasibility of using Hexoskin cardiorespiratory and activity data, as well as patient symptomatology, to provide an AI model for disease progression that will be at the service of the clinical team to recommend the best customized and evolving care trajectory for each patient.

NCT ID: NCT04452643 Withdrawn - Covid19 Clinical Trials

Efficacy of BACMUNE (MV130) in the Prevention of Disease Due to COVID-19 Infection in Healthcare Personnel

Bacmune
Start date: October 2020
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to assess the effect of immunotherapy with the bacterial preparation MV130 on the spread and course of SARS-CoV-2 infection in highly exposed subjets, as is the case with healthcare personnel.

NCT ID: NCT04452474 Withdrawn - COVID-19 Clinical Trials

Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).

Start date: June 30, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the efficacy of a single dose of OKZ (64 mg) vs placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection (COVID-19) at Day 29.

NCT ID: NCT04444687 Withdrawn - COVID Clinical Trials

COVID 19: Is SARS-CoV-2 Contaminating Surgical Aerosols From Laparoscopy and Open Abdominal Surgery?

LapCoVIDSurg
Start date: August 2020
Phase:
Study type: Observational

This study aims at answering the question if aerosols from laparoscopic or open abdominal surgery contain SARS-CoV-2 virus and need to be considered contagious.